BIOSYNEX SA: 2025 Review and Outlook for 2026

In 2025, BIOSYNEX recorded revenue of €95.1 million, a 6% decrease compared to the previous year. After adjusting for currency and scope changes, the actual decline was 4%. The decrease in sales, particularly of Covid-19 self-tests, contrasts with the increase in thermotherapy. The DIAGNOSTIC USA Division reduced its exports, focusing on the domestic market where margins are higher.

For 2026, the group plans to intensify its efforts on high value-added products. The Pharmaceuticals Division expects to strengthen its presence through an agreement with Universal®. Emphasis will also be placed on the development of diagnostics for biotherapies and sexually transmitted infections in the USA.